Standout Papers

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2020 2026 2022 2024551
  1. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2020)
    Chris Parker, Elena Castro et al. Annals of Oncology
  2. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial (2023)
    Fred Saad, Noel W. Clarke et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 4 from Science/Nature 61 standout
Sub-graph 1 of 20

Citing Papers

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
2023 Standout
A neutrophil response linked to tumor control in immunotherapy
2023 Standout
3 intermediate papers

Works of Giuseppe Procopio being referenced

The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice
2019
Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP)
2017
and 1 more

Author Peers

Author Last Decade Papers Cites
Giuseppe Procopio 2967 2618 1201 1488 353 5.0k
Haruyasu Murakami 3640 3763 889 1361 304 6.0k
Tomoyuki Yokose 3266 2603 808 1185 270 6.5k
Seiji Niho 2902 3127 540 1093 213 4.9k
Kiyotaka Yoh 2533 2911 726 1319 269 4.5k
Maria Di Bartolomeo 2316 4586 834 882 247 6.3k
Anna S. Berghoff 3114 3702 893 1521 290 7.1k
Heine H. Hansen 2539 4110 693 1527 197 6.5k
Philip Bonomi 4349 4803 961 2075 240 7.8k
Hagen F. Kennecke 1399 3534 1847 1320 154 5.4k
Takashi Seto 6507 5971 1160 2199 362 8.5k

All Works

Loading papers...

Rankless by CCL
2026